• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification.

作者信息

Xue Jihao, Yin Qijia, Wang Ming, Li Yanling

机构信息

Department of Neurosurgery, the Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Department of Urology or Nursing, Dazhou First People's Hospital, Dazhou, Sichuan, China.

出版信息

Front Immunol. 2024 Dec 18;15:1499286. doi: 10.3389/fimmu.2024.1499286. eCollection 2024.

DOI:10.3389/fimmu.2024.1499286
PMID:39744629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11688399/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9b/11688399/8fbb022694b2/fimmu-15-1499286-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9b/11688399/8fbb022694b2/fimmu-15-1499286-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9b/11688399/8fbb022694b2/fimmu-15-1499286-g001.jpg

相似文献

1
Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification.评论：类磷光蛋白3是胶质瘤中一种新型的预后和肿瘤免疫生物标志物：一项经实验验证的多组学分析
Front Immunol. 2024 Dec 18;15:1499286. doi: 10.3389/fimmu.2024.1499286. eCollection 2024.
2
Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification.Phosducin-like 3 是胶质母细胞瘤的一种新的预后和肿瘤免疫生物标志物：一项具有实验验证的多组学分析。
Front Immunol. 2023 Mar 15;14:1128151. doi: 10.3389/fimmu.2023.1128151. eCollection 2023.
3
Multi-Omics Analysis Based on Genomic Instability for Prognostic Prediction in Lower-Grade Glioma.基于基因组不稳定性的多组学分析用于低级别胶质瘤的预后预测
Front Genet. 2022 Jan 5;12:758596. doi: 10.3389/fgene.2021.758596. eCollection 2021.
4
Identification of a Nomogram with an Autophagy-Related Risk Signature for Survival Prediction in Patients with Glioma.用于预测胶质瘤患者生存的具有自噬相关风险特征的列线图的识别
Int J Gen Med. 2022 Feb 15;15:1517-1535. doi: 10.2147/IJGM.S335571. eCollection 2022.
5
LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification.LncRNA RP3-525N10.2-NFKB1-PROS1 三重介导的低 PROS1 表达是低级别胶质瘤中的一种癌免疫生物标志物：具有实验验证的泛癌症分析。
J Transl Med. 2022 Jul 25;20(1):335. doi: 10.1186/s12967-022-03536-y.
6
Cox Regression in Glioma Prognosis Analysis: Challenges with the Proportional Hazards Assumption and Coping Strategies. Comment on Ou Y, . " as a Prognostic Biomarker and Potential Therapeutic Target in Glioma". Frontiers in Bioscience-Landmark. 2024; 29: 144.胶质瘤预后分析中的Cox回归：比例风险假设面临的挑战及应对策略。对欧Y等人《作为胶质瘤预后生物标志物和潜在治疗靶点》一文的评论。《生物科学前沿-地标》。2024年；29卷：第144页。
Front Biosci (Landmark Ed). 2024 Oct 14;29(10):353. doi: 10.31083/j.fbl2910353.
7
Limitations of nomogram models in predicting survival outcomes for glioma patients.列线图模型在预测神经胶质瘤患者生存结局方面的局限性。
Front Immunol. 2025 Mar 18;16:1547506. doi: 10.3389/fimmu.2025.1547506. eCollection 2025.
8
Characterization of METTL7B to Evaluate TME and Predict Prognosis by Integrative Analysis of Multi-Omics Data in Glioma.通过多组学数据综合分析对METTL7B进行表征以评估胶质瘤的肿瘤微环境并预测预后
Front Mol Biosci. 2021 Sep 17;8:727481. doi: 10.3389/fmolb.2021.727481. eCollection 2021.
9
Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.TCGA泛癌队列中转录组数据的Cox回归模型中比例风险假设的违反情况。
Comput Struct Biotechnol J. 2022 Jan 7;20:496-507. doi: 10.1016/j.csbj.2022.01.004. eCollection 2022.
10
The Prognostic Value of the Prognostic Nutritional Index in Operable High-Grade Glioma Patients and the Establishment of a Nomogram.预后营养指数在可手术的高级别胶质瘤患者中的预后价值及列线图的建立
Front Oncol. 2022 Jan 14;11:724769. doi: 10.3389/fonc.2021.724769. eCollection 2021.

本文引用的文献

1
Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification.Phosducin-like 3 是胶质母细胞瘤的一种新的预后和肿瘤免疫生物标志物：一项具有实验验证的多组学分析。
Front Immunol. 2023 Mar 15;14:1128151. doi: 10.3389/fimmu.2023.1128151. eCollection 2023.
2
Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models.评估生存结局预测模型的性能和临床实用性：Cox 比例风险模型的实用指南。
Ann Intern Med. 2023 Jan;176(1):105-114. doi: 10.7326/M22-0844. Epub 2022 Dec 27.
3
Why Test for Proportional Hazards?
为什么要检验比例风险？
JAMA. 2020 Apr 14;323(14):1401-1402. doi: 10.1001/jama.2020.1267.
4
If the ratio of hazards r(t)=λe(t)/λc(t) does not depend on time t then the proportional hazards assumption holds.如果风险比r(t)=λe(t)/λc(t)不依赖于时间t，则比例风险假设成立。
J Thorac Oncol. 2013 Dec;8(12):e116. doi: 10.1097/JTO.0b013e3182a4081f.
5
Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models.急性淋巴细胞白血病患者造血干细胞移植后生存时间的预后因素：Cox比例风险模型与加速失效时间模型
J Exp Clin Cancer Res. 2008 Nov 23;27(1):74. doi: 10.1186/1756-9966-27-74.
6
Time-dependent covariates in the Cox proportional-hazards regression model.Cox比例风险回归模型中的时间相依协变量。
Annu Rev Public Health. 1999;20:145-57. doi: 10.1146/annurev.publhealth.20.1.145.
7
The risk of determining risk with multivariable models.使用多变量模型确定风险的风险。
Ann Intern Med. 1993 Feb 1;118(3):201-10. doi: 10.7326/0003-4819-118-3-199302010-00009.